In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), and reduced the price target to $40 (from $45), following the company’s second-quarter results, in which ESPR reported a share count of 22.5 million that was 9% above Amusa’s expectation of 20.6 million.
Amusa noted, “The timing of milestones was broadly unchanged, and ESPR produced new data on ETC-1002 efficacy and safety that do little to mitigate our concerns. We therefore now emphasize that the failure for Takeda’s TAK-475 in 2008, the year Pfizer sold ETC-1002 to Esperion for $5 million, is a concerning precedent for ESPR shares and reiterate our Sell rating. (TAK-475 was another drug, like ETC-1002, working upstream/downstream of statins and was suboptimally also tested with moderate-intensity statins. We understand regulators wanted to see superiority for TAK-475 over existing therapies, so it was discontinued.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Gbola Amusa has a total average return of 17.0% and a 66.7% success rate. Amusa has a 30.0% average return when recommending ESPR, and is ranked #339 out of 3728 analysts.
Out of the 8 analysts polled by TipRanks, 7 rate Esperion Therapeutics stock a Buy, while 1 rates the stock a Sell. With a return potential of 106.0%, the stock’s consensus target price stands at $117.75.